Evidence map›Paper›PMID 34575126›Full record

ArticleLife (Basel, Switzerland)2021

Dystrophin Dp71 Subisoforms Localize to the Mitochondria of Human Cells.

Emma Tabe Eko Niba, Hiroyuki Awano, Tomoko Lee, Yasuhiro Takeshima, Masakazu Shinohara, Hisahide Nishio, Masafumi Matsuo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024
    Review
  3. Article
  4. In-Frame Deletion of Dystrophin Exons 8-50 Results in DMD Phenotype.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Emma Tabe Eko NibaDepartment of Community Medicine and Social Healthcare Science, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.ORCID 0000-0002-1311-3448
Hiroyuki AwanoDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.ORCID 0000-0001-9846-4142
Tomoko LeeDepartment of Pediatrics, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.ORCID 0000-0002-1064-1202
Yasuhiro TakeshimaDepartment of Pediatrics, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.ORCID 0000-0002-6468-7185
Masakazu ShinoharaDepartment of Community Medicine and Social Healthcare Science, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Hisahide NishioDepartment of Occupational Therapy, Faculty of Rehabilitation, Kobe Gakuin University, Kobe 651-2180, Japan.
Masafumi MatsuoDepartment of Physical Therapy, Faculty of Rehabilitation, Kobe Gakuin University, Kobe 651-2180, Japan.ORCID 0000-0001-6747-7194
Kobe University · JPHyogo Medical University · JPKobe Gakuin University · JP

Funding

Japan Society for the Promotion of Science 16k07216
6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disease caused by deficiency in dystrophin, a protein product encoded by the

Indexed as

Dp71 subisoformsDuchenne muscular dystrophydystrophinmitochondria

Identifiers

PMID34575126
PMCPMC8468555
OpenAlexW3200905950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.